Request Demo
FibroGen, former employees settle dispute over alleged trade secrets theft
Phase 3Executive ChangePatent Infringement
Under a settlement, neither FibroGen nor China’s Andao Pharmaceutical or California-based Kind Pharmaceuticals are on the hook for any type of payment or compensation.
Nearly a year and a half aftFibroGenGen slapped a pair of former employees with a lawsuit Kind Pharmaceuticalsts theft, both the plaintiffs and the defendants are walking away from the case little worse for wear.
China’s Andao Pharmaceutical anFibroGenrnia-based Kind Pharmaceuticals, along with the latter company’s CEO and chief scientific officer, Dong Liu, Ph.D., and Shaojing Deng, Ph.D., this week announced a mutual agreement with FibroGen to withdraw legal proceedings in the trade secrets spat.
Neither FibroGen nor Andao or Kind are on the hookKind Pharmaceuticalsment or compensation, according to a press release issued by Kind.FibroGen
FibroGenFibroGenlly sAndaoiu and Deng in December 2022 for allegedly pinching proprietary information and filing improper patents around hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors (HIF-PHIs)—a class of drug used to treat anemia that includes FibroGen’s Astellas- and AstraZeneca-partnered roxadustat.
FibroGenDeng worked as scientists at FibroGen for years. In 2013, two years before leaving FibroGen, Liu founded Kind, according to a couhypoxia-inducible factor prolyl hydroxylase enzymeadership position in 2019.anemiaFibroGenAstraZenecaroxadustat
In its case, FibrHangzhou Andao Pharmaceuticals hatched an “international scheme” to give Kind an “unlawful head start” in order to FibroGenears of research developing and identifying HIF-PHI compounds with clinical efficacy.”
FibroGen origFibroGenought to stop Kind from using its proprietary information and pressure the company to list FibroGen as the true owner on its HIF-PHI patents. FibroGen also wanted compensation and for its former employees to forfeit any profits made from patents they “wrongfully” claimed.
"Kind is pleased that these disputKind Pharman fully and finally resolved,” Liu HIF-PHI a statemenAND017th these disputes behind us, Kind can now focus on advancing its innovative pipAND017of products to the market.”anemiacancer-related anemia
As for FibroGen’s roxadustat, the drug has fallen victim to a string of setbacks in the U.S. that culminated in late February with AstraZeneca returning the rights to FibroGen for the HIF-PHI in a range of territories outside China and South Korea, where it’s approved under the brand name Evrenzo.
The decFibroGenme roxadustatls of a phase 3 trial flop and an FDA complete response letter for roxadustat in anemia associated withAstraZenecadney disease in the U.S.FibroGenHIF-PHIEvrenzo
Outside China and Korea, Astellas has a deal with FibroGen to FDAket Evrenzo in Japan and Europroxadustatanemiachronic kidney disease
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.